Commercial Credit Report for Pharnext SCA

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Pharnext SCA is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Pharnext SCA
14 rue de la Republique
Phone: +33 141092230p:+33 141092230	SURESNES, 92150 France	Ticker: ALPHAALPHA

Business Summary

Pharnext SA is a France-based biopharmaceutical company. The Company is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The Company's prime focus is on neurodegenerative diseases and metabolic diseases.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	Yes	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
6/30/2023	12/31/2022	Yes	-	-	-	-

Industries

SIC Code	Description
2834	Pharmaceutical preparations
8731	Commercial physical and biological research

Officers and Directors

Title	Name	Age	Title Date	Start Date
Interim Chairman of the Board	JoshuaSchafer	52	3/30/2022	3/30/2022
Chief Executive Officer, Director	David H.Solomon	63	7/17/2020	7/17/2020
Co-founder and Director	PhilippePouletty	65
12 additional Officers and Directors records available in full report.

General Information

Number of Employees:	44	(As of 12/31/2019)
Outstanding Shares:	78	(As of 2/15/2024)
Stock Exchange:	EPA
Fax Number:	+33 141092231